Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. on October 7, 2019, for the month of October 2019. The filing announces a corporate action regarding the Company's American Depositary Receipt (ADR) program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure adjustment rather than financial performance results.
Material Changes
- ADR Ratio Change: The Company announced a 5:1 reverse split of its ADR program. Each American Depositary Share (ADS) will represent 100 ordinary shares, increased from the previous 20 ordinary shares.
- Effective Date: The anticipated effective date for the ratio change is October 23, 2019.
- Nasdaq Compliance: The Company previously received notice on May 16, 2019, of non-compliance with Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price requirements. The ratio change is intended to proportionally increase the ADS price to meet this requirement.
- Shareholder Impact: ADS holders must surrender old ADSs for cancellation at a rate of one new ADS for every five old ADSs. No fractional ADSs will be issued; cash will be paid in lieu of fractions. The change does not alter the Company's share capital or a holder's ownership percentage, barring minor adjustments from fractional share treatment.
Outlook, Risks, and Management Commentary
Management anticipates that the ratio change will result in a proportional increase in the ADS price, potentially satisfying the Nasdaq minimum bid price requirement. However, the filing explicitly states there can be no assurance that such an increase will occur or that the Company will successfully regain compliance.
Investor Verification Checklist
- Confirm the effective date of the 5:1 ADR ratio change (anticipated October 23, 2019).
- Verify the current trading status of the ADS on the Nasdaq Capital Market following the ratio change.
- Check for any subsequent filings regarding the Company's compliance with Nasdaq Listing Rule 5550(a)(2).
- Review the treatment of fractional ADSs and the cash payment mechanism for holders.